

# **LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis**

Bioscience Reports. 2019. 39. BSR20181335.

## **Research No.(5): Multiple Authers**

### **Abstract**

Longnon-codingRNAs(lncRNAs)playanimportantroleingeneregulationandshowgreater tissue specificity and complexity of biological functions. There is on-going research in their contribution in autoimmune diseases like multiple sclerosis (MS). Our study aimed at the evaluation of serum levels of lncRNAs, MALAT1 and lnc-DC in MS patients and the investigation of the association between these lncRNAs and the disease activity. Serum from 45 MS patients and 45 healthy controls was separated. MALAT1 and lnc-DC expression levels were assayed by qRT-PCR. MALAT1 and lnc-DC were significantly increased in MS patients ( $P=0.004$  and  $P=0.006$ , respectively) in comparison with controls. There was a significant increase in expression of MALAT1 in secondary progressive MS (SPMS) subgroup compared with controls ( $P<0.0001$ ); however, significant elevation of lnc-DC was demonstrated in relapsing remitting MS (RRMS) subtype ( $P=0.003$ ) compared with normal controls. A positive association between the expression level of MALAT1 and lnc-DC ( $r=0.513, P<0.0001$ ) in MS patients was detected. Moreover, positive correlation was observed between MALAT1 and lnc-DC in RRMS ( $r = 0.569, P = 0.001$ ). Serum levels of MALAT1 and lnc-DC may serve as potential novel molecular biomarkers for MS diagnosis and may provide a new direction for its treatment.